MicroRNA-124 Regulates Fatty Acid and Triglyceride Homeostasis

HIGHLIGHTS

- miR-124 regulates triglyceride and fatty acid metabolism
- miR-124 represses genes associated with fatty acid and triglyceride breakdown
- miR-124 promotes triglyceride accumulation in hepatoma cells
MicroRNA-124 Regulates Fatty Acid and Triglyceride Homeostasis

Tyler A. Shaw, 1,3 Ragunath Singaravelu, 1,3 Megan H. Powdrill, 1 Jordan Nhan, 1 Nadine Ahmed, 1 Dennis Özcelik, 1 and John Paul Pezacki 1,2,4,*

SUMMARY
MicroRNAs (miRNAs) are part of a complex regulatory network that modulates cellular lipid metabolism. Here, we identify miR-124 as a regulator of triglyceride (TG) metabolism. This study advances our knowledge of the role of miR-124 in human hepatoma cells. Transcriptional profiling of Huh7.5 cells overexpressing miR-124 reveals enrichment for host factors involved in fatty acid oxidation among repressed miRNA targets. In addition, miR-124 down-regulates arylacetamide deacetylase (AADAC) and adipose triglyceride lipase, lipases proposed to mediate breakdown of hepatic TG stores for lipoprotein assembly and mitochondrial β-oxidation. Consistent with the inhibition of TG and fatty acid catabolism, miR-124 expression promotes cellular TG accumulation. Interestingly, miR-124 inhibits the production of hepatitis C virus, a virus that hijacks lipid pathways during its life cycle. Antiviral activity of miR-124 is consistent with repression of AADAC, a pro-viral host factor. Overall, our data highlight miR-124 as a novel regulator of TG metabolism in human hepatoma cells.

INTRODUCTION
Fatty acids serve as an important energy source for mammals in the fasted state (Houten and Wanders, 2010). The liver is the central organ in fatty acid metabolism, responsible for fatty acid uptake from serum, de novo lipid synthesis, and fatty acid oxidation or secretion in the form of lipoproteins (Mashek, 2013). Fatty acid oxidation serves to produce acetyl CoA, nicotinamide adenine dinucleotide (NADH), and flavin adenine dinucleotide (FADH2). NADH and FADH2 serve as electron carriers to feed into the electron transport chain to generate ATP. Both saturated and unsaturated fatty acids are broken down through reactions catalyzed in both mitochondria and peroxisomes. Although the key enzymes catalyzing fatty acid breakdown have been elucidated, the regulatory mechanisms governing fatty acid oxidation are not fully understood.

Under pathological conditions, hepatic fatty acid trafficking can be disrupted, resulting in increased fatty acid storage in the form of triglycerides (TGs). This manifests clinically as hepatic steatosis, as observed in hepatitis C virus (HCV) infection and fatty liver disease (Ress and Kaser, 2016). In the case of viral infection, the pathogen may manipulate fatty acid flux to create specific lipid-rich microenvironments to facilitate its life cycle (Chukkapalli et al., 2012). Proper regulatory controls on metabolic gene networks are integral to maintaining proper energy homeostasis and preventing hepatic metabolic disorders.

Recent work has demonstrated that microRNAs (miRNAs) are crucial to proper regulation of hepatic TG homeostasis (Moore et al., 2011). These small RNAs, ranging in size from 21 to 24 nucleotides, modulate gene expression through partial pairing with mRNAs, generally in the 3’ untranslated region (3’ UTR) (Pasquinelli, 2012). Canonical miRNA targeting of mRNAs results in a combination of transcript destabilization and translation repression (Pasquinelli, 2012). These small RNAs simultaneously regulate multiple targets within the same pathway (Ben-Hamo and Efroni, 2015). The critical role of miRNAs in the maintenance of hepatic lipid homeostasis has been established, with several miRNAs regulating aspects of fatty acid oxidation, lipid biosynthesis, and lipid excretion (Li et al., 2017; Moore et al., 2011; Singaravelu et al., 2014, 2015a, 2018). For example, miR-122 has been shown to extensively modulate hepatic lipid microenvironments (Esau et al., 2004). Given the abundance of the miRNA in the liver, it has been found to be directly involved in modulating cholesterol and hepatic fatty acid metabolism (Elmén et al., 2008; Esau et al., 2006; Krutzfeldt et al., 2005). In addition, modulation of HCV replication by miR-122 has been well established (Jopling et al., 2005). A thorough understanding of the functional role of miRNAs in hepatic fatty acid metabolism is critical to properly define the etiology of metabolic disorders.
Recent studies have demonstrated the involvement of miR-124-3p (miR-124) in hepatobiliary pathologies (Liu et al., 2016; Ning et al., 2014). Expression of miR-124 has been shown to be directly regulated by the liver-enriched transcription factor, hepatocyte nuclear factor 4α (Ning et al., 2014). Recent work demonstrated that hepatic delivery of the miRNA suppresses tumorigenesis in mice (Ning et al., 2014). To date, miR-124 has mainly been examined in the context of processes in the central nervous system, where it is highly expressed (Sun et al., 2015), whereas its physiological function in the liver remains poorly studied. Herein, we examine the role of miR-124 in hepatic lipid homeostasis. Our data suggest a novel role for this miRNA in the metabolic stress response. Genome-wide expression profiling reveals that miR-124 concertedly represses multiple genes involved in fatty acid oxidation and TG hydrolysis. Through repression of these catabolic pathways, miR-124 promotes hepatocellular TG storage. Interestingly, we also demonstrate that miR-124 impairs the infectivity of HCV, a hepatotropic virus with a strong dependence on hepatic lipid pathways for its propagation. Overall, our work demonstrates that miR-124 is a novel regulator of fatty acid homeostasis and HCV infection.

RESULTS

miR-124 Expression Is Modulated during HCV Infection and Serum Depletion

The antiviral oxysterol 25-hydroxycholesterol (25-HC) plays an important role in regulating the immune response to viral infection. The oxysterol has multifaceted effects through modulation of lipid metabolism and inflammatory and stress response pathways (Singaravelu et al., 2015b). Recent work by our group identified numerous miRNAs that are differentially expressed following treatment with 25-HC (Singaravelu et al., 2015a). One of these 25-HC-regulated miRNAs, hsa-miR-124-3p (miR-124), has been shown to play a role in liver disease (Liu et al., 2016; Ning et al., 2014).

We sought to examine whether miR-124 plays a functional role in the liver. Based on its regulation by 25-HC, we hypothesized that miR-124 is dysregulated during metabolic stresses in hepatocytes. We first measured the expression of the miRNA during serum depletion. We found that cultivation of Huh7.5 hepatoma cells for 48 hr in serum-free media increased miR-124 expression approximately 2-fold compared with normal culturing conditions (Figure 1A). We also considered viral infection as another source of metabolic stress, which could influence miR-124 expression. HCV is a hepatotropic virus that alters liver metabolism to facilitate its viral life cycle. Our previous work (Singaravelu et al., 2015a), along with others’ (Vallianou et al., 2016), demonstrated that HCV infection decreases miR-124 expression. We reproduced this finding using a cell-culture-adapted high-titer strain of HCV (Russell et al., 2008). Forty-eight hours post-infection, we observed a 2-fold decrease in miR-124 expression levels (Figure 1B). Taken together, these results demonstrate that miR-124 levels are modulated during metabolic stresses (i.e., serum depletion and HCV infection) and point toward a metabolic regulatory role for the miRNA in liver cells.
miR-124 Targets Genes with Functional Roles in Fatty Acid Catabolism

To investigate the hepatic pathways regulated by miR-124, we performed gene expression profiling in Huh7.5 cells transfected with control (Con-miR) or miR-124 mimic. A summary of the top 10 up- and down-regulated genes is given in Table S1. To identify the direct targets of miR-124 in the hepatic cells, we examined the overlap between predicted targets of miR-124 (4,450 genes as per TargetScan; Agarwal et al., 2015) and genes repressed by miR-124 mimic transfection by over 1.5-fold (1,693 genes). For our analysis, a cutoff of 1.5-fold was utilized given that direct targeting of a specific gene by a single miRNA may induce modest overall changes in the gene’s expression. However, cooperative targeting of multiple genes, involved in the same pathway, by a single miRNA may induce more pronounced phenotypic changes (Bonci et al., 2008; Hashimoto et al., 2013). The overlap produced a list of 425 genes. Bioinformatics analysis via the ToppGene Suite (Chen et al., 2009), was performed to identify associated pathways enriched in this list of repressed miR-124 targets. Interestingly, fatty acid degradation and metabolism were the only two significantly enriched pathways (Table S2; p < 0.05). We then used qRT-PCR to validate miR-124-mediated repression of genes in the fatty acid β-oxidation pathway bearing putative miR-124-binding sites in their 3’ UTR (Figure 2A). We analyzed the expression of HADH, HADHA, HADHB, PECR, ACADVL, ECI2, CPT1A, ACAA2, and ACADSB. Consistent with the microarray results, each of these genes’ expression was found to be down-regulated by qRT-PCR (Figures 2A, S1, and S2). Notably, miR-124’s repression of CPT1A expression is consistent with previous work demonstrating that this gene is a direct miR-124 target in prostate cancer cells (Valentino et al., 2017). Immunoblot analyses further confirmed similar reduction of HADHA and ECI2 protein levels (Figure 2B). Interestingly, serum starvation of Huh7.5 cells, which promotes miR-124 expression, results in a significant decrease in ACADSB expression, consistent with physiologically relevant miR-124 repression of this gene during metabolic stress (Figure S2A). This is further supported by
rescue of ACADSB expression during serum starvation by miR-124 inhibition (Figure S3B). The sum of miR-124’s repressive effects on these individual genes should result in a greater overall effect of miR-124 on fatty acid oxidation.

Carnitine is a key cofactor that enables shuttling of acyl-CoAs into the mitochondria. Long-chain fatty acids are otherwise impermeable to the mitochondria. Closer examination of the microarray results revealed a down-regulation in the expression of SLC25A20, a gene encoding carnitine-acylcarnitine translocase, which mediates transport of acyl carnitines across the inner mitochondrial membrane; ALDH9A1, a gene encoding 4-trimethylaminobutyraldehyde dehydrogenase, which is proposed to be involved in the hepatic synthesis of carnitine, a key cofactor for the transfer of long-chain fatty acids to mitochondria for oxidation; and SLC22A5, a transporter for carnitine uptake from serum (Figures S1 and S2) (Strijbis et al., 2010). qRT-PCR also validated the down-regulation of these three miR-124 targets in Huh7.5 cells transfected with miR-124 mimics (Figure 2C). Collectively, these data demonstrate that miR-124 is involved in the repression of carnitine homeostasis and fatty acid oxidation.

miR-124 Promotes Cellular TG Accumulation

Inhibition of fatty acid oxidation results in an accumulation of free fatty acids, which can be incorporated into TGs for storage. Therefore, we hypothesized that miR-124 overexpression would influence cellular TG levels. We assayed TG levels in control and miR-124-mimic-transfected Huh7.5 cells and observed a significant increase in cellular TG levels (Figure 3A), in line with miR-124’s repression of fatty acid oxidation (Figure 2). Similarly, oil red O staining revealed an increase in cellular lipid levels during miR-124 mimic transfection (Figure 3B). Collectively, our data demonstrate that miR-124 promotes hepatocellular TG accumulation.

miR-124 Inhibits Expression of Triglyceride Hydrolases

We sought to identify additional targets of miR-124, which could contribute to miR-124’s induction of TG accumulation. Hydrolysis of TG stores mediates mobilization of fatty acids for very-low-density lipoprotein synthesis or as substrates for fatty acid oxidation. Therefore, repressed expression of TG hydrolases (TGHs) could also contribute to miR-124-induced increase in cellular TG levels. We noted that aryldiacetamide deacetylase (AADAC), an endoplasmic reticulum-localized carboxylester hydrolase that hydrolyzes TGs (Lo et al., 2010), was among the most highly miR-124-repressed genes in our microarray data (Table S1). Down-regulation at the transcriptional level was verified by qRT-PCR (Figure 4A), and immunoblot analysis confirmed that protein levels were also decreased in the miR-124-mimic-treated cells (Figure 4B). The microarray data also revealed decreased carboxylesterase 1 (CES1) and NR1H4 expression. CES1 is another hydrolase responsible for TG breakdown, whereas NR1H4 encodes for the farnesoid X receptor (FXR). Neither gene possesses miR-124-binding sites in their 3’ UTR. FXR is a nuclear hormone receptor, which regulates the clearance of hepatic TGs, in part through induced expression of CES1 (Phulukdaree et al., 2015). qRT-PCR analysis validated an over 7.6-fold decrease in CES1 and an over 3.5-fold decrease in NR1H4 expression levels (Figure 4A). Surprisingly, we did not observe a down-regulation of CES1 protein expression levels; however, a recent study suggests that the half-life of the CES1 protein is approximately
96 hr (Ross et al., 2012). This suggests that the timescale of our miR-124 overexpression experiments (72 hr) may not have been sufficient to enable observation of miR-124's repressive effect on CES1 expression. Lastly, we observed miR-124-mediated repression of PNPLA2 expression in the microarray data. This miR-124 target gene encodes adipose triglyceride lipase (ATGL), a hepatic lipase responsible for mediating hepatic TG hydrolysis and channeling hydrolyzed fatty acids to β-oxidation (Ong et al., 2011). This is consistent with our qRT-PCR data (Figure 4A), and previous reports demonstrating miR-124-mediated repression of PNPLA2 expression in adipocytes (Das et al., 2015). Collectively, concordant repression of TG hydrolysis and fatty acid oxidation should contribute to TG accumulation mediated by miR-124 overexpression in hepatic cells.

**miR-124 Inhibits HCV Infection**

We and others have identified several miRNAs that are differentially expressed during infection with HCV, promoting either pro- or antiviral environments via modulation of genes involved in lipid pathways (Li et al., 2017; Shirasaki et al., 2013; Singaravelu et al., 2014, 2015a). We postulated, given HCV's strong reliance on hepatic lipid pathways to facilitate its life cycle, that miR-124, through regulation of TG homeostasis, could influence viral infectivity. miR-124 overexpression in Huh7.5 cells decreased viral infectivity and repressed the expression of miR-124 targets (Figure S4). This is consistent with a previous study demonstrating that decreased expression of AADAC impairs production of HCV (Nourbakhsh et al., 2013). Our work suggests that miR-124 inhibits HCV infection through inhibition of AADAC expression.

**DISCUSSION**

miRNAs have emerged as a key regulatory layer in the maintenance of hepatic lipid homeostasis (Moore et al., 2011). However, there are limited examples of miRNAs playing key roles in the regulation of TG catabolism. Hepatic miR-33 has been shown to regulate several key enzymes in the fatty acid oxidation pathway (Davalos et al., 2011). Herein, we identify a novel function for miR-124 in the regulation of TG catabolism via multiple key enzymes involved in fatty acid oxidation and TG hydrolysis. Through concerted targeting of multiple genes, miR-124 produces a cooperative inhibitory effect on lipid catabolism, resulting in hepatocellular TG accumulation (Figure 5). This highlights an emerging theme in miRNA regulation whereby miRNAs have evolved to target multiple genes in the same pathway to produce a greater overall regulatory effect.

Our work demonstrates that miR-124 suppresses the expression of several key enzymes in the mitochondrial β-oxidation pathway (ACADVL, ACADSB, HADHA, HADHB, HADH, and ACAA2). ACADVL encodes the mitochondrial membrane-bound long-chain acyl-CoA dehydrogenase (VLCAD), which is responsible for the first step of the mitochondrial fatty acid oxidation cycle for saturated long-chain fatty acids (14–20 carbons). VLDAC catalyzes the dehydrogenation of acyl-CoAs to trans-Δ2-enoyl-CoA. ACADSB performs an analogous dehydrogenation reaction for short/branched fatty acids. HADHA and HADHB

![Figure 4. miR-124 Down-Regulates Genes associated with Triglyceride Hydrolysis](image-url)

(A) Relative mRNA expression levels of PNPLA2, CES1, NR1H4, and AADAC in control and miR-124-mimic-transfected cells as assessed by qRT-PCR analysis (n > 5). Data are represented as the mean ± SEM (*p < 0.05).

(B) Immunoblot analysis of protein expression levels of AADAC in miR-124- or control mimic- (Con-miR) transfected Huh7.5 cells. Three independent biological replicates are shown, and total protein detection serves as loading control. Blot is cropped to emphasize relevant bands.
form a hetero-octamer complex, called the mitochondrial trifunctional protein, responsible for catalyzing the last three steps of fatty acid oxidation for long-chain fatty acids. Specifically, HADHA is responsible for catalyzing trans-$\Delta^2$-enoyl CoA hydration to form L-3-hydroxyacyl-CoA, and the subsequent dehydrogenation to 3-ketoacyl CoA; then HADHB sequentially catalyzes long-chain keto-acyl-CoA thiolase activity producing an acetyl-CoA and an acyl-CoA. For short- and medium-chain fatty acids, HADH and ACAA2 catalyze the last two steps of the oxidation. For unsaturated fatty acids, cis-enoyl-CoA esters have to be transformed to trans configurations to enable their catabolism. ECI2 contributes to the catabolism of unsaturated fatty acids by catalyzing an isomerization of cis-$\Delta^3$ and trans-$\Delta^3$-enoyl CoA esters into trans-$\Delta^2$-enoyl-CoA esters. Fatty acid oxidation can also be catalyzed in the peroxisome, with the participation of a different set of enzymes, including PECR, which encodes a peroxisomal trans-$\Delta^2$-enoyl-CoA reductase. Collectively, our data highlight miR-124 as a regulator of multiple key nodes in both peroxisomal and mitochondrial $\beta$-oxidation.

Our data demonstrate that miR-124 down-regulates proteins responsible for carnitine uptake from plasma (SLC22A5), carnitine synthesis (ALDH9A1), and acyl-CoA conjugation of carnitine (CPT1A), as well as translocation of acyl-CoA-carnitine through the inner mitochondrial membrane (SLC25A20). As the CPT1A-catalyzed acyl transfer to carnitine represents one of the rate-limiting steps of fatty acid oxidation, this suggests that targeting of CPT1A by miR-124 should enable the miRNA to exert greater regulatory control over fatty acid oxidation.

A subset of the genes repressed by miR-124 do not possess canonical seed sites, suggesting a non-canonical or indirect mode of regulation. A previous study, which utilized Argonaute 2 (Ago2) co-immunoprecipitation...
followed by mRNA microarray analysis to identify miR-124 targets in HEK293 cells, suggested that miR-124-loaded Ago2 directly interacted with the 3’ UTR of HADHB mRNA (Karginov et al., 2007). A subsequent study confirmed this interaction in mice brains using high-throughput sequencing of RNAs isolated by Ago cross-linking immunoprecipitation (Chi et al., 2009). Close examination of the 3’ UTR reveals a potential miR-124 “G-bulge” site (Figure S5), which is a recently described non-canonical miRNA-binding motif where a G nucleotide bulge is allowed in the mRNA (in the corresponding nucleotide position 5–6 of the miRNA) (Chi et al., 2012). Another potently repressed gene, AADAC, possesses no mRNA-binding sites in the 3’ UTR to the best of our knowledge; however, examination of the open reading frame (ORF) reveals the presence of one canonical site. Typically, ORF-binding sites are less prone to miRNA regulation; however, if the sites are preceded by a stretch of rare codons, the recognition site may be functional (Gu et al., 2009). Examination of the three codons upstream of the binding site reveal three rare codons (usage <12%; Figure S6), suggesting that miR-124 may regulate AADAC through a functional ORF-binding site. This implies that miR-124 regulates a subset of its metabolic gene targets using non-canonical mode of target recognition.

Several of the miR-124 targets have been established as targets of the transcription factor peroxisome proliferator-activated receptor α (PPAR-α), including HADHA, HADHB, ACA2, ACADVL, SLC25A20, SLC22A5, and CPT1A (Rakhshandehroo et al., 2010). This nuclear hormone receptor acts as a master transcriptional regulator of mitochondrial and peroxisomal fatty acid oxidation and is activated as part of the fasting response (Kersten et al., 1999). Although several of our described targets have been validated as direct targets of miR-124 in other systems, we postulate that decreased PPAR-α signaling is a major contributor to the observed reduction in fatty acid oxidation gene expression during miR-124 overexpression. This is in line with decreased expression of the TGHs ATGL and CES1, which has previously been correlated with decreased PPAR-α activity (Xu et al., 2014). Also, AADAC overexpression has been shown to promote fatty acid oxidation in rat hepatoma cells (Lo et al., 2010). Therefore miR-124-mediated repression of these TGHs should result in an indirect repression of fatty acid oxidation.

Our miRNA expression analysis revealed that serum depletion activates miR-124 expression (Figure 1A). Interestingly, a recent study demonstrated that statin treatment of hepatoma cells induces miR-124 expression (Phulukdaree et al., 2015). Together, these data suggest that metabolic stresses regulate miR-124 expression. In statin-treated mice, increased mitochondrial and peroxisomal fatty acid oxidation has been observed in the liver (Park et al., 2016), suggesting that statin-induced miR-124 expression may serve to buffer this increase in fatty acid oxidation.

Previous work suggested that miR-124 promotes hepatic TG synthesis through regulation of TRIB3 (Liu et al., 2016) and enhanced hepatic lipogenesis. We did not, however, observe increased expression of lipogenic genes (SREBPs and FASN; Figures S1 and S5) or repression of TRIB3 (Figure S1). This could be a result of a variation in models used (Huh7.5 vs. mice), but our data strongly suggest that the observed miR-124-induced TG accumulation in Huh7.5 cells is due to decreased TG and fatty acid breakdown, as opposed to increased lipogenesis.

Also, miR-124 was previously identified as a broadly antiviral miRNA against murine cytomegalovirus, murine herpesvirus 68, and herpes simplex virus 1 during a genome-wide functional miRNA screen (Santhakumar et al., 2010). The same group later confirmed that the miRNA’s antiviral activity extended to influenza A virus strains and respiratory syncytial virus (McCaskill et al., 2017). In the latter study, the authors ascribed this antiviral activity, in part, to the regulation of p38 mitogen-activated protein kinase (MAPK) signaling. Although we cannot exclude the contribution of the p38 MAPK signaling pathway to the observed anti-HCV effects of miR-124, given the strong dependence of HCV on hepatic lipid pathways, miR-124’s regulation of hepatocellular metabolism likely contributes to the its influence on HCV. It is important to note that our previous work, using an HCV replicon model, suggests that miR-124 promotes HCV replication (Singaravelu et al., 2015a). In contrast, this work employing a full-length virus (JFH-1) suggests that, in a model fully recapitulating the entire viral life cycle, miR-124 inhibits HCV infectivity. This is consistent with miR-124 regulation of AADAC, the only positive regulator of virion production identified among our miR-124 targets (Nourbakhsh et al., 2013).

Overall, our data highlight a novel functional role for miR-124 in hepatic TG catabolism. This metabolic-stress-regulated miRNA concordantly regulates multiple nodes within the TG hydrolysis and fatty acid
oxidation pathways, yielding a greater overall effect on TG homeostasis. It is interesting to note that there are several miRNAs that target metabolic pathways in the liver at different nodes. These miRNAs cooperate, often in a redundant fashion, to fine-tune metabolic networks in the liver and manage the homeostatic response to multiple inputs (e.g., from the muscle and fat). Future work should examine the function of miR-124 in the context of systemic energy homeostasis.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

Limitations of Study
We demonstrated that miR-124 inhibits the expression of genes associated with fatty acid and TG metabolism in the Huh7.5 hepatoma model. Further analysis is required to elucidate the role of this miRNA regulatory axis in vivo.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, six figures, and three tables and can be found with this article online at https://doi.org/10.1016/j.isci.2018.11.028.

ACKNOWLEDGMENTS
J.P.P. is supported by grant funding from the Canadian Institutes of Health Research (CIHR), Canada (220886) and Natural Sciences and Engineering Research Council of Canada (NSERC), Canada (210719). R.S. received graduate student funding from the Canadian Network on hepatitis C and is the recipient of post-doctoral funding from the Life Science Research Foundation. M.H.P. received post-doctoral funding from the Canadian Network on Hepatitis C. D.O. is the recipient of post-doctoral scholarship from the Natural Sciences and Engineering Research Council of Canada. mRNA microarray profiling was performed by The Center for Applied Genomics (TCAG), The Hospital for Sick Children, Toronto, ON, Canada. Gene expression profiling data from miR-124 and control mimic-transfected Huh7.5 cells have been deposited to NCBI Gene Expression Omnibus under the following accession number: GSE122134.

AUTHOR CONTRIBUTIONS
Conceptualization, J.P.P., R.S., and M.H.P.; Methodology, R.S., M.H.P., and T.A.S.; Formal Analysis, R.S., M.H.P., T.A.S., D.O., and J.P.P.; Investigation, M.H.P., T.S., J.N., N.A., and J.P.P.; Writing – Original Draft, R.S., T.A.S., M.H.P., N.A., and J.P.P.; Review & Editing, all authors; Funding Acquisition, R.S. and J.P.P.; Supervision, R.S., M.H.P., and J.P.P.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: June 12, 2018
Revised: October 1, 2018
Accepted: November 15, 2018
Published: December 21, 2018

REFERENCES
Agarwal, V., Bell, G.W., Nam, J.W., and Bartel, D.P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, e05005.

Ben-Hamo, R., and Efroni, S. (2015). MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype. Oncotarget 6, 1594–1604.

Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeeo, L., D’Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14, 1271–1277.

Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305–W311.

Chi, S.W., Hannon, G.J., and Darnell, R.B. (2012). An alternative mode of microRNA target recognition. Nat. Struct. Mol. Biol. 19, 321–327.

Chi, S.W., Zang, J.B., Mele, A., and Darnell, R.B. (2009). Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460, 479–486.

Chukkapalli, V., Heaton, N.S., and Randall, G. (2012). Lipids at the interface of virus-host interactions. Curr. Opin. Microbiol. 15, 512–518.

Das, S.K., Stadelmeyer, E., Schauer, S., Schwarz, A., Strohmaier, H., Claudel, T., Zechnier, R., Hoefler, G., and Vesely, P.W. (2015). MicroRNA-124a regulates lipolysis via adipose triglyceride lipase.

iScience 10, 149–157, December 21, 2018
lipase and comparative gene identification 58. Int. J. Mol. Sci. 16, 8535–8568.

Davalos, A., Goedeke, L., Smibert, P., Ramirez, C.M., Warrier, N.P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J.C., et al. (2011). miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. U.S.A. 108, 9232–9237.

Elmén, J., Lindow, M., Silharataglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjarn, M., Hansen, J.B., Hansen, H.F., Straarup, E.M., et al. (2008). Antagonism of microRNA-122 in mice by systemically administered LNA-antiMiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153–1162.

Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Botten, S.L., Graham, M., McKay, R., et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87–98.

Gü, S., Jin, L., Zhang, F., Sarnow, P., and Kay, M.A. (2009). Biological basis for restriction of microRNA targets to the 3’ untranslated region in mammalian mRNAs. Nat. Struct. Mol. Biol. 16, 144–150.

Hashimoto, Y., Akiyama, Y., and Yuasa, Y. (2013). Multiple-to-multiple relationships between MicroRNAs and target genes in gastric cancer. PLoS One 8, e62589.

Houten, S.M., and Wanders, R.J. (2010). A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J. Inherit. Metab. Dis. 33, 469–477.

Jopling, C.L., Miyi, M., Lancaster, A.M., Lemon, S.M., and Sarnow, P. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 1, 1577–1581.

Karginov, F.V., Conaco, C., Xuan, Z., Schmidt, J.P., Kawahara, T., Lisboa, L.F., Wei, E., Asthana, S., Quiroga, A.D., Law, L.M., et al. (2013). Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. J. Hepatol. 59, 336–343.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., and Hannon, G.J. (2004). The adaptive response to fasting. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Proc. Natl. Acad. Sci. U S A 101, 1489–1498.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Kersten, S., Seydoux, J., Peters, J., Gonzalez, F.J., Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.

Krugtelfeld, J., Rajewsky, N., Braich, R., Rajeev, K.G., Busch, T., Schiavo, G., and Hannon, G.J. (2007). A biochemical approach to identifying microRNA targets. Proc. Natl. Acad. Sci. U S A 104, 19291–19296.
Supplemental Information

MicroRNA-124 Regulates Fatty Acid and Triglyceride Homeostasis

Tyler A. Shaw, Ragunath Singaravelu, Megan H. Powdrill, Jordan Nhan, Nadine Ahmed, Dennis Özcelik, and John Paul Pezacki
Supplementary Information

MicroRNA-124 regulates fatty acid and triglyceride homeostasis

Tyler A. Shaw¹,³, Ragunath Singaravelu¹,³, Megan H. Powdrill¹, Jordan Nhan¹, Nadine Ahmed¹, Dennis Özcelik¹, John Paul Pezacki¹,²,⁴,*

¹Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada
²Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
³These authors contributed equally.
⁴Lead contact

*Correspondence: john.pezacki@uottawa.ca
**Transparent Methods**

**Materials**

The human hepatocellular carcinoma cell line Huh7.5 was a kind gift from Dr. Charles M. Rice (Rockefeller University, New York, NY). All *mir*Vana mimics and inhibitors, along with controls, were purchased from Ambion (Austin, TX).

**Cell culture, transfections, and viral infection**

Huh7.5 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 nM non-essential amino acids. For transfections of uninfected cells, cells were seeded in 6-well plates. The following day, the transfection mixture containing RNAiMax (Thermo Fisher Scientific) and the miRNA control mimic/inhibitor or miR-124 mimic/inhibitor at a final concentration of 100 nM in Opti-MEM was added to the cells. For RNA analysis, after 48 h, cells were harvested in RLT Plus lysis buffer (RNeasy Plus kit, Qiagen, Mississauga, ON). For western blot analysis, cells were lysed 48 h post-transfection in 1X SDS lysis buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, and 10% glycerol).

Serum starvation experiments were performed by seeding Huh7.5 cells in 6-well plates and growing cells in serum free media for 48 h. Cells were then lysed using ML Buffer (NucleoSpin miRNA Isolation Kit lysis buffer; Macherey-Nagel, Düren, Germany).

HCV infections of Huh7.5 cells were performed with the HCV JFH1 strain. This strain is derived from the cell culture-adapted JFH-AM1 strain and contains three amino acid substitutions (Russell et al., 2008). Briefly, cells were infected at an MOI of 0.1 then virus was removed following a 5 h infection. Forty-eight hours post infection, supernatant was collected for virus titration and cells were lysed in ML Buffer (Macherey-Nagel) for RNA extraction. For examining miRNA's antiviral effects, Huh7.5 cells were transfected with 100 nM of miRNA...
mimic (control or miR-124). Twenty-four hours post-transfection, cells were infected with HCV JFH1T. At 48 h post-infection, cell supernatants were removed and used for infectious titer determination, and cells were lysed with RLT Plus lysis buffer (Qiagen) for RNA isolation.

**Quantitative real-time PCR**

RNA was quantified using a NanoDrop (Thermo Fisher Scientific). Reverse transcription of 250 ng of RNA was performed with random hexamers using a SuperScript II Reverse Transcriptase kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. qPCR was subsequently performed on a CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA) using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) according to the manufacturer’s instructions. Primers were added to a final concentration of 500 nM in a total reaction volume of 10 µL. Primers used for qPCR are listed in Table S3. All primers were validated prior to use with melt curves and standard curves. For determination of miRNA expression levels, 5 ng total RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies), and qPCR reactions were performed using TaqMan Universal PCR Mastermix (No AmpErase UNG; Life Technologies) with primers specific for miR-124 or RNU6B. For both mRNA and miRNA quantification, the $2^{-\Delta\Delta Ct}$ method was used to calculate fold changes in expression relative to control samples, with 18S rRNA or RNU6B levels being used for normalization (Schmittgen, 2001).

**Immunoblotting**

Lysates were thawed and passed through a 21G needle (BD Biosciences) before determining their protein concentration by DC assay (Bio-Rad). SDS-PAGE was performed using 10 to 20 µg of protein lysate loaded on a 12% TGX gel (Bio-Rad) and the migrated proteins were visualized
on a ChemiDoc MP (Bio-Rad) using the Stain Free activation protocol for 5 min. The migrated proteins were then transferred onto a PVDF membrane using a Trans-Blot Turbo (Bio-Rad) Membranes were then blocked with 5 % BSA or 5 % milk in TBS-T prior to incubation with primary antibodies. The membrane was then probed with either mouse anti-AADAC (1:1000 dilution; Santa Cruz Biotechnology, sc-390591), mouse anti-HADHA (1:1000 dilution, Santa Cruz Biotech., sc-374497), or mouse anti-PECI (1:1000 dilution, Santa Cruz Biotech., sc-136374) followed by goat anti-mouse antibody conjugated to horseradish peroxidase (1:20000; Jackson ImmunoResearch Laboratories, Inc., 115-035-062). Blots were visualized with Clarity ECL Western blotting reagents (Bio-Rad) on a ChemiDoc MP (Bio-Rad). Stain-free detection of total protein loading was used for the control. Blot images were cropped and adjusted for contrast using Image Lab (Bio-Rad).

**Triglyceride assays**

Triglyceride levels were quantified by spectrophotometric analyses, using the TG quantification kit (BioVision) as per manufacturer’s protocols, with a few minor modifications. Cells were lysed from a 6-well plate in 5 % NP-40 substitute (BioShop, Canada) in water. Samples were diluted 1 in 10 in TG assay buffer; then 50 uL was added to a 96-well plate in duplicate, with and without lipase. The remainder of the protocol mirrored the manufacturer’s protocol.

**Oil red O lipid staining and Microscopy**

Huh7.5 were seeded in 4-well chamber slides. The next day cells were transfected with 100 nM of miRNA mimic (control or miR-124). 48h post-transfection, cells were washed with 1X with PBS and then fixed with 10% formaldehyde for 10 mins at RT. Following the incubation, 10% formaldehyde was replaced with fresh 10% formaldehyde and incubated at RT for an hour. Fixed cells were then washed 2X with water and incubated for 5 minutes with 60%
isopropanol. Cells were completely dried before incubation with 60% isopropanol containing oil red O for 10 minutes. Oil Red O (sigma) stock solution was prepared at 0.35% final concentration in isopropanol and filtered through 0.2μm filter. Cells were immediately washed 5X with water and chamber slide was then mounted with ProLong™ Gold Antifade Mountant with DAPI (Thermofisher). Images were then acquired with Axiophot fluorescence microscope (Zeiss) attached to a DP-70 Colour CCD camera (Olympus) with a 50W mercury fluorescence excitation light source. Images were taken using ImagePro 6 software suite (mediaCybernetics) and analyzed using ImageJ (NIH).

**Infectivity assay**

Supernatants of HCV infected cells were filtered through a 45 μm PES filter (Ultident, Saint-Laurent, Canada) before being serially diluted 10-fold in medium. For HCV infectivity assays, 100 μL of each dilution was then used to infect Huh7.5 cells seeded (at 5×10⁴ per well) onto 8-well Lab-Tek II chamber slides (NUNC) for 4 h. Following incubation, the infectious medium was removed and replaced with fresh medium. Forty-eight hours post infection, cells were fixed and stained with HCV core monoclonal antibody (1:100; ThermoFisher Scientific; MA1080), followed by a secondary antibody, Alexa Fluor 488–conjugated goat anti-mouse (1:250; ThermoFisher Scientific; A-11029). Viral titers are expressed as the number of focus-forming units (FFU) per mL of supernatant.

**mRNA microarray**

RNA isolation from Huh7.5 cells was performed with the RNeasy kit (Qiagen). Gene expression profiling was performed using Affymetrix Human Gene ST.2.0 arrays. Data was normalized and analyzed using the Applied Biosystems Transcriptome Analysis Console (v4.0), according to the
manufacturer’s protocols. Pathway enrichment analysis was performed on genes repressed by miR-124 more than 1.5-fold and predicted by TargetScan (Agarwal et al., 2015), irrespective of conservation, to be a miR-124 target. This analysis was performed using the ToppGene Suite (Chen et al., 2009). For ToppGene pathway enrichment analysis, \( P \)-values were adjusted with Bonferroni correction.

**Supplemental References**

Agarwal, V., Bell, G.W., Nam, J.W., and Bartel, D.P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005.

Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305-W311.

Russell, R.S., Meunier, J.C., Takikawa, S., Faulk, K., Engle, R.E., Bukh, J., Purcell, R.H., and Emerson, S.U. (2008). Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. USA 105, 4370-4375.

Schmittgen, T.D. (2001). Real-time quantitative PCR. Methods 25, 383-385.
Supplementary Figure S1. Microarray gene expression analysis in miR-124 transfected mimic Huh7.5 cells. Related to Figure 2. Fold changes in gene expression of select lipid-metabolism-related genes in Huh7.5 cells transfected with 100 nM of miR-124 mimic are shown. Fold changes were calculated relative to gene expression in 100 nM control mimic-transfected Huh7.5 cells.
a miR-124-3p UAGGCA CGCGGUGAAUGCC

b CPT1A (ENST00000265641.5)
  3 miR-124 binding sites
  3'UTR position 641-648
  . . . AGUC UUCAC AACCCA GUGCCUUA . . .
  3'UTR position 1240-1246
  . . . GUCC UCA AUCAGG GUGCUU C . . .
  3'UTR position 1506-1512
  . . . CUUGCCGGAGAACAC GUGCUU . . .

c ACADVL (ENST00000356839.5)
  1 miR-124 binding site
  3'UTR position 31-37
  . . . GCCUGUCCAGUUAU GUGCUU C . . .


d ACADSB (ENST00000358776.4)
  1 miR-124 binding site
  3'UTR position 75-81
  . . . UCUUGUUGGAGUAAG GUGCUU G . . .

e ECI2 (ENST00000380118.3)
  1 miR-124 binding site
  3'UTR position 87-93
  . . . UAAAUAAGCUCAUCU GUGCUU U . . .

f HADHA (ENST00000380649.3)
  1 miR-124 binding site
  3'UTR position 136-142
  . . . UGCUCCCUAGUUAA GUGCUU U . . .

g SLC25A20 (ENST00000430379.1)
  1 miR-124 binding site
  3'UTR position 141-151
  . . . ACUUGGUGAGACUGU GUGCUU AA . . .

h PNPLA2 (ENST00000336615.4)
  1 miR-124 binding site
  3'UTR position 189-196
  . . . AGGGCGGCACCU GUGCUU A . . .

i ACAA2 (ENST00000285093.10)
  2 miR-124 binding sites
  3'UTR position 291-297
  . . . AGUAA CACC ACUUC GUGCUU A G . . .
  3'UTR position 331-337
  . . . AAAUCAAAUAAGUUG GUGCUU A . . .

j HADH (ENST0000040312.1)
  1 miR-124 binding site
  3'UTR position 251-257
  . . . AGCUUUA CACC CUGU GUGCUU G . . .

k PECR (ENST00000265322.7)
  2 miR-124 binding sites
  3'UTR position 32-38
  . . . GUCCUC AUC CCCCAC GUGCUU C . . .
  3'UTR position 792-798
  . . . CUUAGGACAAUAAU GUGCUU J . . .

l ALDH9A1 (ENST00000354775.4)
  1 miR-124 binding site
  3'UTR position 181-187
  . . . GAAAAUGCAUUAAG GUGCUU G . . .

m SLC22A5 (ENST00000245407.3)
  1 miR-124 binding site
  3'UTR position 1290-1296
  . . . GUGAAAGCUACUGAA GUGCUU G . . .
**Supplementary Figure S2. miRNA recognition elements in direct targets of miR-124.**
related to Figures 2 & 4. (a) Sequence of mature miR-124 with seed sequence highlighted in yellow. Sequence of miR-124 binding sites in the 3’UTRs of (b) CPT1A, (c) ACADVL, (d) ACADSB, (e) EC12 (f) HADHA, (g) SLC25A20, (h) PNPLA2, (i) ACAA2, (j) HADH, (k) PECR, (l) ALDH9A1 and (m) SLC22A5. Sequences were taken from TargetScan. Seed sequences are highlighted in yellow, and nucleotides predicted to be involved in supplementary interactions with the 3’ end of miR-124 are highlighted in green.
Supplementary Figure S3. Expression of ACADSB during serum depletion and miR-124 inhibition, related to Figure 2. (A) Huh7.5 cells were cultured in complete or serum-free media for 48 h. qRT-PCR was performed to measure relative ACADSB expression (n = 4). (B) Huh7.5 cells were transfected with control or miR-124 inhibitor for 6 hours and were then cultured in complete or serum-free media for 48 hours. qRT-PCR was performed to measure relative ACADSB expression (n = 2). Data are represented as the mean ± SEM (*P < 0.05).
Supplementary Figure S4. miR-124 regulates HCV infection, related to Figures 2 & 4. (A) Relative HCV production and (B) miR-124 target expression in control (Con-miR) and miR-124 mimic transfected Huh7.5 cells infected with HCV. Viral production was assessed by a focus-forming assay while target expression was measured via qRT-PCR analysis. Data are represented as the mean ± SEM.
Supplementary Figure S5. miR-124 G-bulge binding site in HADHB 3’UTR, Related to Figure 2. miR-124 G-bulge recognition sites are highlighted in red and bold for all three HADHB transcripts isoforms (NCBI reference sequences shown).
ATGGGAAGAAAATCGCTGTTGATTTGTTGGGACAGCATATGATTTATATATTATAGCTCTCCAGATTTTGCTTCATTTGCTGAGCTCCTTGGAGGACTTACAGCATATTATATTATATGCATCTGAACCTGACAGGATGTGAGTAATGTGGTAGATATAACG CACATCTGAAAAGTATACAAAATTTTGGCTACATTGTTGAGCTCCTTGGGACTTACAC ATTTTTATGTTACCTTTAAAGGTGTTGCTGGGAGCTTTTGTGAGAITCAGCACCACAACCCTCA GATGAAAAATGTCACTGAGCTGAGACAAATTTCAAAACATTTCCTTGGGATATAT GTGCCAAGAGAAAGTCTGGAAGCACTAAGAGGGGTGTTTTACACATCTGATTGGA GAGGCTGTTGCGTGAGAGAGTGCCTCAAGTGTGATTAGCTGCTGTCAGATG GACAGCAGACAGACCTTGATGCTGCTGCTGATCAACCAACTACAGATTAGCAACCTCA AGATCTATTTCCCAATTAATGTGAAAGTGGTGTCTTTAC GTAAAAAGGTTCTTGCAAAATATGTTGTTGAACCTGAGGAATCGGTATTGCTTGGAG TAGTGACAGGAGGAAATTAGGCTGACAGGTACTCAACAGCTCTTGTGTGACC CAGATGTCAAGATCAAATCAAGATTTCTAGTTGGAATTTTTATTCTGCTGCTTGCCTTCAGCTTCTGATGTAGATTACCGTCAAGATTTCTTCTATTTCTATCCAAATC ACTCATGTCAGATTTCTGAGTGAATTGTTTTACCCTAGATAGATCAGATCTAGGAAAAAGC CATGCTTTTCAGCAACATGATCTTTGCAGAATCAGTATCCTCTTTCAATTTGTTAAT TTGGAGCTTCCCTGCTCTCTGAGAGGTTTATAAAGGACATGTTTTAACAATCCAAA TTAATGAGCAGTTCTGAGCCTGCTTAAAAATATCCAGGTTGCTAGATGTGAGGCGCAG CCCCTTGGTGGCTGAGCAACAAATTACGTGCTTACCCTGACCTATGTCATC ACCTGTCAGATATGATCTTTAAGAGATGAGGGACTGATCTGATGTCACCAGCTTCAG CAACACTGGGGTTCAAGGTGACTCATAACCAGATTGTTGAGGATACCAATGGGACT GTTCAATTTCTGGGACCTAAAATTAGTCACAGACACTTAAAATACAGTATATTTAGTTGGGCTAAAGGAAAACTATAG 

**Supplementary Figure S6. miR-124 binding site in AADAC ORF**, related to Figure 4. Sequence for AADAC ORF is shown (NCBI: NM_001086.2). The miR-124 binding site is shown in red letters, while the three rare codons are underlined and highlighted in yellow.
Table S1. Summary of top up- and down-regulated genes from microarray analysis of miR-124 mimic transfected Huh7.5 cells, Related to Figure 2.

| Gene Symbol | Description | Fold Change |
|-------------|-------------|-------------|
| **Top up-regulated genes** | | |
| SLC2A2 | solute carrier family 2 (facilitated glucose transporter), member 2 | 16.97 |
| BEX1 | brain expressed X-linked 1 | 12.08 |
| RANBP3L | RAN binding protein 3-like | 11.48 |
| LOC101927482 | uncharacterized LOC101927482 | 11.07 |
| CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 | 8.65 |
| LOC105375361 | uncharacterized LOC105375361 | 6.84 |
| B3GALT1 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 1 | 6.68 |
| KCNJ3 | potassium channel, inwardly rectifying subfamily J, member 3 | 6.34 |
| KIF5C | kinesin family member 5C | 6.22 |
| DIO1 | deiodinase, iodothyronine, type I | 6.21 |
| **Top down-regulated genes** | | |
| IQGAP1 | IQ motif containing GTPase activating protein 1 | -5.75 |
| CP | ceruloplasmin (ferroxidase) | -5.76 |
| LGALS3 | lectin, galactoside-binding, soluble, 3 | -5.92 |
| AIM1 | absent in melanoma 1 | -6.01 |
| TNFSF4 | tumor necrosis factor (ligand) superfamily, member 4 | -6.02 |
| HEPACAM2 | HEPACAM family member 2 | -6.50 |
| CD38 | CD38 molecule | -6.99 |
| AADAC | arylacetamide deacetylase | -8.40 |
| VAMP3 | vesicle associated membrane protein 3 | -9.11 |
| HP | haptoglobin | -15.69 |
Table S2. Gene ontology analysis classifying genes repressed by >1.5 fold in miR-124 mimic transfected Huh7.5 cells by biological process, Related to Figure 2.

| Name                      | Source             | P-value†          |
|---------------------------|--------------------|-------------------|
| Fatty acid metabolism     | SMPDB              | 1.63E-2           |
| Fatty acid degradation    | BioSystems: KEGG   | 1.65E-2           |

*Only biological processes with $P < 0.05$ are listed.

†Adjusted with Bonferroni correction.
Table S3. List of oligonucleotides used in this study, related to Figures 2 & 4.

| Oligonucleotide | Sequence          |
|-----------------|-------------------|
| qPCR primers    |                   |
| 18S rRNA – FWD  | GAGCTCCTGGGACTTCACCAT |
| 18S rRNA – REV  | ATCTGGGTCATCAAGGAGCTGT |
| AADAC – FWD     | CTGCTCCAGGTGTGTTTGA |
| AADAC – REV     | GGCAGCAAATTCAGACAACTCA |
| ACADSB – FWD    | GATGGGAAATGTAGACCCCTACC |
| ACADSB – REV    | AAGGCCCGGAGATTACAG |
| ACADVL – FWD    | TAGGAGAGGAGGCAAACAGCT |
| ACADVL – REV    | CACAGTGGCAAAACTGCTCCAGA |
| CPT1A – FWD     | TCCAGTTTGCTTATCGTG |
| CPT1A – REV     | TCCAGAGTCCGATTGATT |
| ECI2 – FWD      | TTCAACCGGCCCAAAAAGAAA |
| ECI2 – REV      | ATTCCTTCAGTAIAACGCATT |
| HADHA – FWD     | AAATTGACAGCGTATG |
| HADHA – REV     | GCTTTTGCACTTCCCC |
| JFH1 HCV – FWD  | GTCTGGGAAACCCGAGTA |
| JFH1 HCV – REV  | GCCCAATGCGGGGATA |
| PECR – FWD      | CGGAAAAGCCATCGTGAAGGAG |
| PECR – REV      | ATGACTCGTGCCTGCTTTTG |
| PPARA – FWD     | CTATCATTTGCTGAGATCG |
| PPARA – REV     | AAGATATTCGTCCGGGGTT |
| PPARGC1A – FWD  | GCTTTCTGCCGACTCAAGT |
| PPARGC1A – REV  | GAGGGCAATCCGCTTTCACTC |
| SLC25A20 - FWD  | CCGAGAACCTGACAGACGGAG |
| SLC25A20 - REV  | CCACAGAAGCAACACCGGCAA |
| CES1 - FWD      | AACTGTCGCCCTCCACGAT |
| CES1 - REV      | CATCCCTGTGCTGAAAGAATCC |
| ALDH9A1 - FWD   | GCAACCAGGCGAGTGATAG |
| ALDH9A1 - REV   | ACCACATTGAAGAGCCCAGG |